{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:23:34Z","timestamp":1769599414698,"version":"3.49.0"},"reference-count":36,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>In December 2019, in Wuhan (PRC), there was an outbreak of a new coronavirus infection (COVID-19) caused by coronavirus type 2 (SARS-CoV-2), which has a zoonotic origin. The World Health Organization announced the COVID-19 pandemic on March 11, 2020. In most cases, the disease is asymptomatic or mild. However, up to 15% of patients require hospitalization, and 5% develop a critical condition. To date, no effective antiviral drug COVID-19 has been found that can reduce mortality. Pathological changes in the lungs are manifested by diffuse alveolar damage, which is clinically manifested by increasing respiratory failure, accompanied by a decrease in saturation and oxygen concentration in arterial blood. It is assumed that autoimmune reactions play an important role in the development of multiple organ failure. Generalized inflammation is characterized by an increase in the concentration of C-reactive protein, ferritin, interleukin-1 and interleukin-6, and other markers. At the stage of development of infection in the form of a cytokine storm, proinflammatory cytokines can themselves become pathogenetic factors in the development of critical conditions, multiple organ failure and deaths. Therefore, a key challenge in treating hospitalized patients with COVID-19 is to control generalized inflammation. Glucocorticosteroid hormones (GCS) are widely used as anti-inflammatory drugs in the clinic of infectious diseases. However, until recently, there was no convincing data on the effectiveness of GCS in patients with COVID-19. Recently published results of a large randomized clinical trial (RECOVERY) showing the efficacy of GCS (dexamethasone) in the treatment of critically ill patients with COVID-19. At the same time, the feasibility and effectiveness of GCS in patients with COVID-19 outside critical conditions, the pathogenetic mechanisms that determine the effectiveness\/ineffectiveness of these drugs and the validity of their use remain insufficiently studied.<\/jats:p>","DOI":"10.26442\/00403660.2021.11.201184","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:54:04Z","timestamp":1643795644000},"page":"1395-1400","source":"Crossref","is-referenced-by-count":1,"title":["The role and place of pathogenetic therapy with glucocorticosteroid hormones in the treatment of patients with novel coronavirus infection (COVID-19)"],"prefix":"10.26442","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-6052","authenticated-orcid":false,"given":"Dmitrii O.","family":"Efremov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-4167","authenticated-orcid":false,"given":"Vladimir B.","family":"Beloborodov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401456"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050541"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(02)00297-8"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(16)32228-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1172OC"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.07.006"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/424016"},{"key":"ref10","unstructured":"Xiao JZ, Ma L, Gao J, Yang ZJ, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi. 2004;43(3):179-82."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030343"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2395-8"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-0642-4"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5332-4"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0047"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1936"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30361-5"},{"key":"ref18","unstructured":"WHO. World Health Organization; Geneva: Jan 28, 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Available at: https:\/\/www.who.int\/publications-detail\/clinical-management-of-severeacuterespiratoryinfectionwhen-novelcoronavirus(ncov)infectionissuspected. Accessed: 15.08.2021."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1807885"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa601"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249481"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000512063"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00355"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02964-w"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00048-2021"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01736"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-017-0123-8"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2015.54594"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01545"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13073"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Almawi WY, Lipman ML, Stevens AC, et al. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol. 1991;146(10):3523-7.","DOI":"10.4049\/jimmunol.146.10.3523"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993,151(7):3460-6.","DOI":"10.4049\/jimmunol.151.7.3460"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Spahn JD, Szefler SJ, Surs W, et al. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996;157(6):2654-9.","DOI":"10.4049\/jimmunol.157.6.2654"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/99727\/73201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/99727\/73201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:31:51Z","timestamp":1674660711000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/99727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2021.11.201184","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}